NURR1 deficiency is associated to ADHD-like phenotypes in mice.
Animals
Attention Deficit Disorder with Hyperactivity
/ genetics
Behavior, Animal
/ physiology
Disease Models, Animal
Dopaminergic Neurons
/ metabolism
Impulsive Behavior
/ physiology
Male
Mice
Mice, Knockout
Motor Activity
/ genetics
Nuclear Receptor Subfamily 4, Group A, Member 2
/ genetics
Spatial Learning
/ physiology
Spatial Memory
/ physiology
Substantia Nigra
/ metabolism
Tyrosine 3-Monooxygenase
/ metabolism
Ventral Tegmental Area
/ metabolism
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
27 08 2019
27 08 2019
Historique:
received:
04
02
2019
accepted:
17
07
2019
revised:
09
06
2019
entrez:
29
8
2019
pubmed:
29
8
2019
medline:
10
3
2020
Statut:
epublish
Résumé
The transcription factor NURR1 regulates the dopamine (DA) signaling pathway and exerts a critical role in the development of midbrain dopaminergic neurons (mDA). NURR1 alterations have been linked to DA-associated brain disorders, such as Parkinson's disease and schizophrenia. However, the association between NURR1 defects and the attention-deficit hyperactivity disorder (ADHD), a DA-associated brain disease characterized by hyperactivity, impulsivity and inattention, has never been demonstrated. To date, a comprehensive murine model of ADHD truly reflecting the whole complex human psychiatric disorder still does not exist. NURR1-knockout (NURR1-KO) mice have been reported to exhibit increased spontaneous locomotor activity, but their complete characterization is still lacking. In the present study a wide-ranging test battery was used to perform a comprehensive analysis of the behavioral phenotype of the male NURR1-KO mice. As a result, their hyperactive phenotype was confirmed, while their impulsive behavior was reported for the first time. On the other hand, no anxiety and alterations in motor coordination, sociability and memory were observed. Also, the number of mDA expressing tyrosine hydroxylase, a rate-limiting enzyme of catecholamines biosynthesis, and DA level in brain were not impaired in NURR1-KO mice. Finally, hyperactivity has been shown to be recovered by treatment with methylphenidate, the first line psychostimulant drug used for ADHD. Overall, our study suggests that the NURR1 deficient male mouse may be a satisfactory model to study some ADHD behavioral phenotypes and to test the clinical efficacy of potential therapeutic agents.
Identifiants
pubmed: 31455763
doi: 10.1038/s41398-019-0544-0
pii: 10.1038/s41398-019-0544-0
pmc: PMC6712038
doi:
Substances chimiques
Nr4a2 protein, mouse
0
Nuclear Receptor Subfamily 4, Group A, Member 2
0
Tyrosine 3-Monooxygenase
EC 1.14.16.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
207Références
Sci Rep. 2016 Aug 01;6:30725
pubmed: 27477597
Cell. 2009 Apr 3;137(1):47-59
pubmed: 19345186
Nat Rev Neurosci. 2007 Jan;8(1):21-32
pubmed: 17180160
Mol Cell Neurosci. 2013 Jan;52:51-61
pubmed: 23000673
Psychopharmacology (Berl). 2013 Jun;227(4):741-9
pubmed: 23397052
Genes Brain Behav. 2015 Sep;14(7):534-42
pubmed: 26178014
Mol Psychiatry. 2007 Aug;12(8):756-66
pubmed: 17457314
J Clin Child Adolesc Psychol. 2007 Apr-Jun;36(2):113-26
pubmed: 17484685
J Neurosci. 2012 Jan 11;32(2):436-51
pubmed: 22238080
Curr Top Behav Neurosci. 2012;9:301-15
pubmed: 21487952
Sci Rep. 2018 Oct 18;8(1):15349
pubmed: 30337626
Curr Protoc Neurosci. 2011 Jul;Chapter 8:Unit 8.26
pubmed: 21732314
Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2360-5
pubmed: 23341612
PLoS One. 2013 Jul 24;8(7):e69381
pubmed: 23894463
Neuropsychiatr Dis Treat. 2018 Oct 30;14:2905-2913
pubmed: 30464474
Science. 1997 Apr 11;276(5310):248-50
pubmed: 9092472
CNS Drugs. 2015;29(10):865-77
pubmed: 26293742
J Neurosci. 2009 Dec 16;29(50):15923-32
pubmed: 20016108
Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 5;133B(1):57-63
pubmed: 15635701
Exp Cell Res. 1999 Dec 15;253(2):737-46
pubmed: 10585298
Behav Brain Res. 2019 Jan 1;356:257-265
pubmed: 30189289
Ann N Y Acad Sci. 2001 Jun;931:33-49
pubmed: 11462751
Schizophr Res. 2006 May;84(1):36-56
pubmed: 16631355
J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S46-53
pubmed: 18480677
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):4013-8
pubmed: 9520484
Exp Neurol. 2005 Jan;191(1):154-62
pubmed: 15589522
J Neurosci. 2010 Jan 27;30(4):1270-87
pubmed: 20107055
Behav Brain Res. 2006 Oct 2;173(1):22-9
pubmed: 16870275
J Psychiatr Pract. 2004 Jan;10(1):39-56
pubmed: 15334986
Neurochem Neuropharmacol. 2017 Jun;3(1):
pubmed: 28989991
Behav Brain Res. 2003 Jul 14;143(1):95-100
pubmed: 12842300
Cell. 2009 Apr 3;137(1):26-8
pubmed: 19345183
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11047-54
pubmed: 11572967
Neurotox Res. 2016 Oct;30(3):338-44
pubmed: 27159982
Genes Brain Behav. 2011 Jul;10(5):589-603
pubmed: 21545404
PLoS One. 2015 Apr 13;10(4):e0122501
pubmed: 25875332
Lancet. 2005 Jul 16-22;366(9481):237-48
pubmed: 16023516
Neuropharmacology. 2009 Dec;57(7-8):687-93
pubmed: 19631228
Prog Neurobiol. 2005 Sep-Oct;77(1-2):128-38
pubmed: 16243425
Hippocampus. 2008;18(1):99-118
pubmed: 17924524
Am J Med Genet. 2000 Dec 4;96(6):808-13
pubmed: 11121187
Mol Cell Neurosci. 1998 May;11(1-2):36-46
pubmed: 9608532
Gene. 1997 Mar 10;187(1):135-9
pubmed: 9073077
Neuroscience. 2003;118(2):297-310
pubmed: 12699766
Behav Brain Res. 2002 Oct 17;136(1):267-75
pubmed: 12385813